RxDoctor Payments Data

Julia St Clair, NP

Nurse Practitioner · Anderson, INNPI 1427480466

Payments from drug & device makers

$5,656in general payments, 2019–2025

Across 383 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$592
  • Takeda Pharmaceuticals U.S.A., Inc.$553
  • Johnson & Johnson$403
  • Ardelyx, Inc.$361
  • Gilead$360
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$5,636100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,656 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$23,330
Medicare patients
165
Services billed
258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab16$468,404
CreonLipase/Protease/Amylase42$138,771
LinzessLinaclotide129$119,472
RezdiffraResmetirom13$49,721
XifaxanRifaximin13$40,585
MotegrityPrucalopride Succinate25$20,850
ErythromycinErythromycin Base21$13,400
Mesalamine ErMesalamine43$13,188
TrulancePlecanatide13$11,397
Ondansetron Hcl20$11,164
Dexlansoprazole DrDexlansoprazole29$6,415
Ursodiol24$5,354
Omeprazole358$4,649
Lubiprostone35$4,640
Colestipol Hcl43$4,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$403$468,40416 claims
AbbVieCreon, Linzess$1,615$258,243171 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$592$51,98126 claims
Madrigal PharmaceuticalsRezdiffra$193$49,72113 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$553$20,85025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →